Structural basis for p38alpha MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity
about
p38 mitogen-activated protein kinase controls NF-kappaB transcriptional activation and tumor necrosis factor alpha production through RelA phosphorylation mediated by mitogen- and stress-activated protein kinase 1 in response to Borrelia burgdorferiStructure-Activity Relationships and X-ray Structures Describing the Selectivity of Aminopyrazole Inhibitors for c-Jun N-terminal Kinase 3 (JNK3) over p38Versatile Loops in Mycocypins Inhibit Three Protease FamiliesSkepinone-L is a selective p38 mitogen-activated protein kinase inhibitorDevelopment of Novel In Vivo Chemical Probes to Address CNS Protein Kinase Involvement in Synaptic DysfunctionX-ray structure of p38α bound to TAK-715: comparison with three classic inhibitorsSpatial analysis and quantification of the thermodynamic driving forces in protein-ligand binding: binding site variabilityA small molecule-kinase interaction map for clinical kinase inhibitorsA chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D.A theoretical entropy score as a single value to express inhibitor selectivity.Virtual screening using a conformationally flexible target protein: models for ligand binding to p38α MAPK.Effects of Water Placement on Predictions of Binding Affinities for p38α MAP Kinase Inhibitors.Inclusion of multiple fragment types in the site identification by ligand competitive saturation (SILCS) approachp38α MAPK and Type I Inhibitors: Binding Site Analysis and Use of Target Ensembles in Virtual Screening.Quantitative evaluation of positive ϕ angle propensity in flexible regions of proteins from three-bond J couplingsStructure and function of Polo-like kinases.TSLP signaling network revealed by SILAC-based phosphoproteomicsHeterocyclic N-Oxides - An Emerging Class of Therapeutic Agents.Structural basis of p38α regulation by hematopoietic tyrosine phosphatase.p38 pathway kinases as anti-inflammatory drug targets.Silibinin Inhibits LPS-Induced Macrophage Activation by Blocking p38 MAPK in RAW 264.7 Cells.An Evaluation of Explicit Receptor Flexibility in Molecular Docking Using Molecular Dynamics and Torsion Angle Molecular Dynamicsp38α mitogen-activated protein kinase inhibitors, a patent review (2005-2011).Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibition.p38 MAPK inhibitors: a patent review (2012 - 2013).A Comprehensive Structural Overview of p38α MAPK in Complex with Type I Inhibitors.Design, Synthesis and Biological Evaluation of Novel Substituted N,N'-Diaryl ureas as Potent p38 Inhibitors.The Discovery of VX-745: A Novel and Selective p38α Kinase Inhibitor.Diaminopyridine-based potent and selective mps1 kinase inhibitors binding to an unusual flipped-Peptide conformationGeneration and characterization of p38beta (MAPK11) gene-targeted mice.Role for mitogen-activated protein kinase p38 alpha in lung epithelial branching morphogenesisRole of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells.Towards a better understanding of the substrate specificity of the UDP-N-acetylglucosamine C4 epimerase WbpP.Data driven polypharmacological drug design for lung cancer: analyses for targeting ALK, MET, and EGFR.Pharmacophore modeling using site-identification by ligand competitive saturation (SILCS) with multiple probe molecules.Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis.Kinetic mechanism for p38 MAP kinase alpha. A partial rapid-equilibrium random-order ternary-complex mechanism for the phosphorylation of a protein substrate.A Comprehensive Structural Overview of p38α Mitogen-Activated Protein Kinase in Complex with ATP-Site and Non-ATP-Site Binders.Description and assessment of a model for GSK-3beta database virtual screening.
P2860
Q24678762-B0505A8B-C0B4-45C2-946B-8F31061C03AFQ27654014-268842AE-EE95-4C5D-87B4-FDF33DB54C56Q27657876-0222D612-A1F3-4B1D-994A-AE88AC37F005Q27676453-A5137679-548D-4275-82B1-9267EC2DC17EQ27679012-079B86E9-474D-4EBB-95AE-C8DAEED7948CQ27681911-C721D7F8-4493-49F9-8D20-E3818ED3F853Q28388743-D0F123CA-D7DD-4486-A378-442CB17771EDQ29617451-D4D02EC2-4DC8-4934-B786-E05B6712F708Q33294239-6A7B3B09-7643-42F5-86CC-81B7C2B763F3Q33870615-5159B880-F36E-4C4B-A170-CEEA404797F8Q34243088-C76D9F85-BFB4-4B3F-A9BE-D5DD9E7DF400Q34530495-5C3FDDE4-A22C-4250-B4B2-81A25F599DC4Q35045753-7BAAF916-FF38-427C-8AE4-67C03B135F83Q35762844-9E6EA83E-7D2D-438C-B1B5-5B7459E61ADDQ35790842-1F3B3454-7C00-4395-9665-65FE8E8FC649Q36004636-81996F6F-F085-4419-9A22-45EA7B65A84FQ36208936-285C3F59-E927-4DCD-8EA1-28ED2DF5B151Q36459685-36410576-DBA5-4CC8-97A1-835398A0DDF6Q36852670-F60D3FD3-3615-43A3-8ADD-59A469EF0CD4Q36919718-59B14635-872C-46C6-8125-954E049BEE0EQ37286265-8D0642E5-38F5-48CC-8354-64A5DBBBD6C6Q37409322-D75A5072-7519-45C3-A857-E1A8681D7651Q37955936-E2FC5092-8B81-49D5-9DEF-7C69D10DC633Q38090663-5E62198A-C585-473E-85CD-129446C1DD31Q38194600-5CE37482-5552-411F-B432-BDC236E72779Q38503202-FFD2BF93-F19F-4B43-B0FF-886FE9E66674Q38963029-F4A87BDE-C6C8-4354-BA6F-704A4D949D00Q39510138-2936811C-9065-4FFA-B760-9407CB9CA81AQ39732994-FA8268F7-7814-4C0B-BAC5-3713FEFF406BQ39891313-5734A3BB-A276-4AD2-B555-C575FC27EC15Q40028122-90193554-4BD7-4A80-AC9C-E87206532724Q40571427-9756B6A5-199A-4297-B202-FDBB8317F542Q41823565-3E1E6504-28BD-4D6D-B7B6-9C3188973887Q42697768-2EAC9966-0319-4BE7-9CD8-DA983CA59D2FQ43161207-E6331C41-C8EF-4E3B-B159-7C07748A60BFQ43234873-52C02CBC-D0B4-4AC4-8350-5B5FEEA19C1DQ46698245-376E3E78-75D8-459E-93F7-FE97BBCA304AQ47324721-1DBECBA4-BAF3-41B7-85D4-09EDB7B55238Q51720330-B091791C-A173-404A-9ED3-B01AF9F6AC3A
P2860
Structural basis for p38alpha MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Structural basis for p38alpha ...... rimidine inhibitor specificity
@ast
Structural basis for p38alpha ...... rimidine inhibitor specificity
@en
Structural basis for p38alpha ...... rimidine inhibitor specificity
@nl
type
label
Structural basis for p38alpha ...... rimidine inhibitor specificity
@ast
Structural basis for p38alpha ...... rimidine inhibitor specificity
@en
Structural basis for p38alpha ...... rimidine inhibitor specificity
@nl
prefLabel
Structural basis for p38alpha ...... rimidine inhibitor specificity
@ast
Structural basis for p38alpha ...... rimidine inhibitor specificity
@en
Structural basis for p38alpha ...... rimidine inhibitor specificity
@nl
P2093
P2860
P356
P1476
Structural basis for p38alpha ...... rimidine inhibitor specificity
@en
P2093
Catherine E Fitzgerald
Dennis Zaller
Joseph W Becker
Patricia M Cameron
Sangita B Patel
Stephen J O'Keefe
Vasilis Bill Pikounis
P2860
P356
10.1038/NSB949
P577
2003-09-01T00:00:00Z